Modification of epigenetic signaling has the potential to serve as a new route in to the treatment of human diseases, including a range of chronic and life-threatening conditions. Epigenomic profiling may form a component of successful Precision Medicine strategies, for conditions with epigenetic and non-epigenetic treatments. Epigenetic modifications are also key mediators of cell fate, with implications for cellular therapies using reprogrammed somatic cells.
WRD is interested in establishing alliances to develop and access:
- Epigenetic targets with a high degree of biological validation
- Novel compounds with epigenetic mechanisms of action
- Epigenomic biomarkers
Specific areas of interest include:
- Validated epigenetic targets with strong mechanism of action support in chronic and life-threatening conditions
- Applications for epigenetically targeted compounds in orphan diseases and genetic conditions
- Epigenomic biomarkers for disease stratification, progression or treatment sensitivity
- Novel epigenetically-targeted compounds with known mechanism of action and defined patient populations
- Selective HDAC inhibitors
Not actively seeking partnering opportunities in:
- Pre-clinical DNA methyltransferase inhibitors for oncology
- Pre-clinical pan-HDAC inhibitors
- Non-coding RNAs (microRNAs, etc.) as systemic therapeutic agents